ANGLE PLC (AIM:AGL, OTCQX:ANPCY) said results using its Parsortix liquid biopsy in a pilot pelvic mass study carried out in conjunction with the Wilmot Cancer Institute have been published in the prestigious Obstetrics & Gynecology (The Green Journal).
Using Parsortix combined with serum protein biomarkers to form a predictive algorithm (MAGIC), malignancy in women with a pelvic mass was detected more effectively than with serum biomarkers alone, ANGLE said.
The study observed 183 women with pelvic mass and a range of benign and malignant conditions.
Dr Richard Moore, director of gynecologic oncology at Wilmot said: "As a leading translational research team with a focus on gynecologic oncology biomarkers, we are excited to present the results of this important study.
“Ovarian cancer is difficult to detect in women with an ovarian cyst or a pelvic mass and identifying patients at high risk is critical.
Professor Kyu Kwang Kim, at Wilmot, added: "This hybrid technology explores the versatility of CTC evaluation in combination with serum biomarkers to improve the detection of cancer. The MAGIC algorithm is an exciting advance towards more effective pelvic mass triage."
Andrew Newland, ANGLE’s chief executive, said gene expression in circulating tumour cells (CTCs) is an emerging field not yet incorporated into existing clinical risk-stratification models for ovarian cancer.
“We now look forward to receiving the headline results from an ongoing clinical verification study in this setting, and we anticipate that the Landscape+ Ovarian assay will be ANGLE's first laboratory-developed test to be offered from our own clinical laboratories."
The research has been published as a peer-reviewed publication in Obstetrics & Gynecology and will be available online at https://angleplc.com/library/publications/ .